Carlo Leonetti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4084182/publications.pdf

Version: 2024-02-01

116 papers	5,378 citations	71102 41 h-index	95266 68 g-index
128 all docs	128 docs citations	128 times ranked	7779 citing authors

#	Article	IF	Citations
1	Antiâ€tumoural activity of the Gâ€quadruplex ligand pyridostatin against BRCA1/2â€deficient tumours. EMBO Molecular Medicine, 2022, 14, e14501.	6.9	13
2	Hybrid Self-Assembling Nanoparticles Encapsulating Zoledronic Acid: A Strategy for Fostering Their Clinical Use. International Journal of Molecular Sciences, 2022, 23, 5138.	4.1	5
3	FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. Journal of Hepatology, 2021, 75, 351-362.	3.7	35
4	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. Journal of Experimental and Clinical Cancer Research, 2021, 40, 364.	8.6	15
5	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. Cancers, 2020, 12, 1830.	3.7	2
6	Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA. International Journal of Pharmaceutics, 2020, 588, 119693.	5.2	19
7	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Journal of Experimental and Clinical Cancer Research, 2020, 39, 279.	8.6	32
8	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 111.	8.6	14
9	Circulating miRNAs in Small Extracellular Vesicles Secreted by a Human Melanoma Xenograft in Mouse Brains. Cancers, 2020, 12, 1635.	3.7	9
10	HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. Hepatology, 2019, 69, 131-142.	7.3	27
11	TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. Nucleic Acids Research, 2019, 47, 3365-3382.	14.5	34
12	Chlorambucil targets <scp>BRCA</scp> 1/2â€deficient tumours and counteracts <scp>PARP</scp> inhibitor resistance. EMBO Molecular Medicine, 2019, 11, e9982.	6.9	26
13	Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein <scp>TRF</scp> 2. EMBO Journal, 2019, 38, .	7.8	49
14	Cell communication and signaling: how to turn bad language into positive one. Journal of Experimental and Clinical Cancer Research, 2019, 38, 128.	8.6	21
15	Xenograft as In Vivo Experimental Model. Methods in Molecular Biology, 2018, 1692, 97-105.	0.9	3
16	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease, 2018, 9, 996.	6.3	75
17	Chitosan-Based Polyelectrolyte Complexes for Doxorubicin and Zoledronic Acid Combined Therapy to Overcome Multidrug Resistance. Pharmaceutics, 2018, 10, 180.	4.5	10
18	Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth. PLoS ONE, 2018, 13, e0203426.	2.5	30

#	Article	IF	Citations
19	Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. Journal of Experimental and Clinical Cancer Research, 2018, 37, 57.	8.6	140
20	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. Cell Death and Differentiation, 2017, 24, 889-902.	11.2	53
21	EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1362-1370.	2.4	17
22	Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?. Journal of Experimental and Clinical Cancer Research, 2017, 36, 189.	8.6	30
23	Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug. Translational Medicine Reports, 2017, 1, .	0.4	0
24	The role of mouse models in translational cancer research: present and future directions. Translational Medicine Reports, 2017, 1, .	0.4	1
25	Patient-derived xenografts: a relevant preclinical model for drug development. Journal of Experimental and Clinical Cancer Research, 2016, 35, 189.	8.6	109
26	Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth. Journal of Biomedical Nanotechnology, 2016, 12, 811-830.	1.1	45
27	Perylene and coronene derivatives binding to G-rich promoter oncogene sequences efficiently reduce their expression in cancer cells. Biochimie, 2016, 125, 223-231.	2.6	21
28	Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance. Nucleic Acids Research, 2016, 44, 1579-1590.	14.5	40
29	Abstract 266: The G-quadruplex ligand EMICORON potentiates the antitumor efficacy of chemotherapy on colon cancer experimental models. , 2016, , .		0
30	A basal level of DNA damage and telomere deprotection increases the sensitivity of cancer cells to G-quadruplex interactive compounds. Nucleic Acids Research, 2015, 43, 1759-1769.	14.5	15
31	A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochemical Pharmacology, 2015, 95, 16-27.	4.4	29
32	Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. Journal of Experimental and Clinical Cancer Research, 2015, 34, 82.	8.6	30
33	Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. Molecular Cancer Therapeutics, 2015, 14, 2541-2551.	4.1	27
34	Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. Oncotarget, 2015, 6, 2779-2793.	1.8	56
35	Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells. Oncotarget, 2015, 6, 32821-32840.	1.8	23
36	Abstract 4237: Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. , 2015, , .		0

#	Article	IF	Citations
37	Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities. Journal of Experimental and Clinical Cancer Research, 2014, 33, 81.	8.6	32
38	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 2945-2957.	14.5	45
39	Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. Journal of Experimental and Clinical Cancer Research, 2014, 33, 71.	8.6	3
40	Evidence for G-quadruplex in the promoter ofÂVEGFR-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 14083-14083.	14.5	0
41	A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides. Journal of Medicinal Chemistry, 2014, 57, 7263-7279.	6.4	53
42	Human placenta-derived neurospheres are susceptible to transformation after extensive in vitro expansion. Stem Cell Research and Therapy, 2014, 5, 55.	5.5	5
43	Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget, 2014, 5, 10446-10459.	1.8	71
44	Antibodyâ€“drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale, 2013, 5, 12278.	5.6	119
45	A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. Journal of Experimental and Clinical Cancer Research, 2013, 32, 72.	8.6	68
46	On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts. Journal of Experimental and Clinical Cancer Research, 2013, 32, 68.	8.6	22
47	TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nature Cell Biology, 2013, 15, 818-828.	10.3	99
48	Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. International Journal of Oncology, 2013, 43, 210-218.	3.3	10
49	Effect of Small Molecules Modulating Androgen Receptor (SARMs) in Human Prostate Cancer Models. PLoS ONE, 2013, 8, e62657.	2.5	20
50	Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biology and Therapy, 2012, 13, 1491-1500.	3.4	57
51	Aromatic Core Extension in the Series of Nâ€Cyclic Bayâ€Substituted Perylene Gâ€Quadruplex Ligands: Increased Telomere Damage, Antitumor Activity, and Strong Selectivity for Neoplastic over Healthy Cells. ChemMedChem, 2012, 7, 2144-2154.	3.2	33
52	New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnology Advances, 2012, 30, 302-309.	11.7	84
53	N-Cyclic Bay-Substituted Perylene G-Quadruplex Ligands Have Selective Antiproliferative Effects on Cancer Cells and Induce Telomere Damage. Journal of Medicinal Chemistry, 2011, 54, 1140-1156.	6.4	51
54	Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene, 2011, 30, 3813-3820.	5.9	76

#	Article	IF	Citations
55	Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. Journal of Cellular and Molecular Medicine, 2011, 15, 316-326.	3.6	5
56	Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 955-964.	3.3	98
57	Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft. Journal of Translational Medicine, 2011, 9, 125.	4.4	11
58	Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. International Journal of Pharmaceutics, 2011, 403, 292-297.	5.2	79
59	DNA Damage Persistence as Determinant of Tumor Sensitivity to the Combination of Topo I Inhibitors and Telomere-Targeting Agents. Clinical Cancer Research, 2011, 17, 2227-2236.	7.0	33
60	Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle, 2011, 10, 1679-1689.	2.6	116
61	PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene, 2010, 29, 6280-6293.	5.9	103
62	Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. Current Cancer Drug Targets, 2010, 10, 368-383.	1.6	18
63	In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells. Current Cancer Drug Targets, 2010, 10, 600-610.	1.6	13
64	Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. Molecular Cancer, 2010, 9, 207.	19.2	91
65	Zinc Downregulates HIF-1Î± and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo. PLoS ONE, 2010, 5, e15048.	2.5	96
66	Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Research, 2009, 37, 5353-5364.	14.5	152
67	Che-1 activates XIAP expression in response to DNA damage. Cell Death and Differentiation, 2008, 15, 515-520.	11.2	32
68	441 POSTER The G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. European Journal of Cancer, Supplement, 2008, 6, 138-139.	2.2	1
69	NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. Nitric Oxide - Biology and Chemistry, 2008, 19, 225-236.	2.7	27
70	G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. Clinical Cancer Research, 2008, 14, 7284-7291.	7.0	82
71	Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting Protein Kinase-2 Knockdown. Cancer Research, 2008, 68, 3707-3714.	0.9	78
72	Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy. Current Pharmaceutical Design, 2007, 13, 463-470.	1.9	33

#	Article	IF	Citations
73	Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. European Journal of Cancer, 2007, 43, 2124-2133.	2.8	128
74	R115777 (ZarnestraÂ®)/Zoledronic acid (ZometaÂ®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. Journal of Cellular Physiology, 2007, 211, 533-543.	4.1	57
75	Therapeutic integration of câ€myc and bclâ€2 antisense molecules with docetaxel in a preclinical model of hormoneâ€refractory prostate cancer. Prostate, 2007, 67, 1475-1485.	2.3	21
76	Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. Journal of Clinical Investigation, 2007, 117, 3236-3247.	8.2	212
77	334 POSTER Combination of c-myc and bci-2 antisense oligonucleotides with docetaxel is highly effective in vitro and in vivo on hormone-refractory prostate cancer. European Journal of Cancer, Supplement, 2006, 4, 104.	2.2	0
78	TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. European Journal of Cancer, 2006, 42, 1881-1888.	2.8	62
79	Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell, 2006, 10, 473-486.	16.8	106
80	Inhibition of poly(ADPâ€ribose) polymerase prevents irinotecanâ€induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB Journal, 2006, 20, 1709-1711.	0.5	97
81	Efficacy of a nitric oxideâ€“releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Molecular Cancer Therapeutics, 2006, 5, 919-926.	4.1	43
82	Antitumor Efficacy of bcl-2 and c-myc Antisense Oligonucleotides in Combination with Cisplatin in Human Melanoma Xenografts: Relevance of the Administration Sequence. Clinical Cancer Research, 2005, 11, 1990-1998.	7.0	28
83	Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. International Journal of Oncology, 2005, 26, 415.	3.3	6
84	Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biology and Therapy, 2005, 4, 866-871.	3.4	15
85	Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. European Journal of Cancer, 2005, 41, 2948-2957.	2.8	37
86	In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. Journal of Translational Medicine, 2005, 3, 7.	4.4	33
87	Biological Activity of the G-Quadruplex Ligand RHPS4 (3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) Is Associated with Telomere Capping Alteration. Molecular Pharmacology, 2004, 66, 1138-1146.	2.3	134
88	Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocrine-Related Cancer, 2004, 11, 407-421.	3.1	34
89	Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effectsin vitro and inhibit spontaneous metastases of human melanoma in mice. International Journal of Cancer, 2004, 110, 125-133.	5.1	42
90	In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. International Journal of Cancer, 2004, 110, 767-774.	5.1	25

#	Article	IF	Citations
91	Lonidamine Causes Inhibition of Angiogenesis-Related Endothelial Cell Functions. Neoplasia, 2004, 6, 513-522.	5.3	29
92	Ras inhibition amplifies cisplatin sensitivity of human glioblastoma. Biochemical and Biophysical Research Communications, 2004, 320, 493-500.	2.1	16
93	?-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. International Journal of Cancer, 2003, 104, 243-250.	5.1	72
94	The future of antisense therapy: combination with anticancer treatments. Oncogene, 2003, 22, 6579-6588.	5.9	79
95	Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy. Journal of Clinical Oncology, 2003, 21, 927-931.	1.6	274
96	Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clinical Cancer Research, 2003, 9, 5370-9.	7.0	160
97	Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood, 2002, 99, 2241-2244.	1.4	83
98	Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. Oncogene, 2002, 21, 3011-3019.	5.9	29
99	A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. European Journal of Cancer, 2001, 37, 2247-2256.	2.8	21
100	Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. Journal of Cellular Biochemistry, 2001, 83, 473-483.	2.6	14
101	In vitro and in vivo inhibition of SK-N-MC neuroblastoma growth using cyclic nucleotide phosphodiesterase inhibitors. Journal of Neuro-Oncology, 2001, 51, 25-31.	2.9	6
102	Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Therapy, 2001, 8, 459-468.	4.6	60
103	Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cellsin vitro and in xenografts. , 2000, 85, 590-596.		48
104	Increased TGFÎ² Type II Receptor Expression Suppresses the Malignant Phenotype and Induces Differentiation of Human Neuroblastoma Cells. Experimental Cell Research, 2000, 255, 77-85.	2.6	11
105	Enhanced Anti-Tumor Effects with Microencapsulated c-mycAntisense Oligonucleotide. Oligonucleotides, 1999, 9, 451-458.	4.3	35
106	N-methylformamide induces changes on adhesive properties and lung-colonizing potential of M14 melanoma cells. British Journal of Cancer, 1998, 77, 210-215.	6.4	4
107	Levels of expression of hRPB11, a core subassembly subunit of human RNA polymerase II, affect doxorubicin sensitivity and cellular differentiation. FEBS Letters, 1998, 427, 241-246.	2.8	8
108	Bclâ€2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB Journal, 1997, 11, 947-953.	0.5	126

#	Article	IF	Citations
109	Functional role of Î±4Î²1 and Î±5Î²1 integrin fibronectin receptors expressed on adriamycin-resistant MCF-7 human mammary carcinoma cells. , 1997, 72, 133-141.		41
110	Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice. Journal of the National Cancer Institute, 1996, 88, 419-429.	6.3	115
111	Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL). Cancer Immunology, Immunotherapy, 1995, 41, 375-383.	4.2	8
112	Temozolomide reduces the metastatic potential of lewis lung carcinoma (3LL) in mice: Role of Î±-6 integrin phosphorylation. European Journal of Cancer, 1995, 31, 746-754.	2.8	18
113	Pharmacological purging of syngeneic bone marrow ex vivo: Effect of treatment with doxorubicin and lonidamine on normal and leukaemic cells of mice. European Journal of Cancer, 1992, 28, 1633-1636.	2.8	2
114	Different effects of sequential combinations ofN-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice. Journal of Cancer Research and Clinical Oncology, 1991, 117, 351-358.	2.5	11
115	Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line. British Journal of Cancer, 1990, 61, 377-381.	6.4	8
116	IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3â€²) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (dimethyl-1-t Immunopharmacology, 1990, 12, 831-840.	1.1	8